Skip to main content
Top
Published in: Rheumatology International 5/2015

01-05-2015 | Original Article - Observational Research

Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study

Authors: Young Bin Joo, Yoon-Kyoung Sung, Jee-Seon Shim, Jae-Hoon Kim, Eui-Kyung Lee, Hye-Soon Lee, Sang-Cheol Bae

Published in: Rheumatology International | Issue 5/2015

Login to get access

Abstract

Avascular necrosis (AVN) is one of the most frequent types of organ damage in systemic lupus erythematosus (SLE). However, little is currently known about the epidemiology of AVN in SLE patients. The aim of this study was to estimate the prevalence and incidence of AVN in Korean patients with SLE based on National Health Insurance (NHI) claims data and to determine the risk factors for AVN among SLE patients. This study was conducted using the 2006–2010 data of 25,358 SLE patients from the NHI program. AVN cases were defined as those with at least one diagnosis of AVN. The prevalence was calculated by dividing the number of AVN cases by the number of SLE cases in the same year. The annual incidence was calculated by dividing the number of incident AVN cases by the number of SLE-prevalent cases not previously diagnosed with AVN. Patients who developed AVN in 2008–2010 were compared with SLE patients who did not develop AVN to identify any risk factors. The prevalence of AVN among SLE patients (2006–2010) was 31.5–34.2 per 1,000 persons and was similar in all the years studied. The incidence per 1,000 persons of AVN among SLE patients was 8.6 [95 % confidence interval (95 % CI) 6.9–10.3] in 2008, 9.8 (95 % CI 8.0–11.6) in 2009, and 8.4 (95 % CI 6.8–10.0) in 2010. Regression analysis indicated that taking an oral corticosteroid [odds ratio (OR) 2.12, 95 % CI 1.39–3.23] or an intravenous corticosteroid (OR 1.5, 95 % CI 1.2–1.89) was significantly associated with AVN. In addition, AVN was associated with use of immunosuppressive agents (OR 2.12, 95 % CI 1.66–2.72), hydroxychloroquine (OR 1.4, 95 % CI 1.09–1.81), and lipid-lowering agents (OR 1.78, 95 % CI 1.24–2.57) among the prescribed medications, and with hypertension (OR 1.39, 95 % CI 1.08–1.79) among the comorbidities. The prevalence and incidence of AVN among SLE patients, which were 31.5–34.2 and 8.4–9.8 per 1,000 persons, respectively, may be representative of the entire population of symptomatic AVN patients with SLE in Korea. AVN is associated with the use of corticosteroids, immunosuppressants, hydroxychloroquine, lipid-lowering agents, and with hypertension. Studies of large, prospective cohorts are needed to confirm these results.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mok MY, Farewell VT, Isenberg DA (2000) Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 59(6):462–467CrossRefPubMedCentralPubMed Mok MY, Farewell VT, Isenberg DA (2000) Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 59(6):462–467CrossRefPubMedCentralPubMed
3.
go back to reference Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O, Onat AM, Avan R, Cetin GY, Gul A, Ocal L, Aral O (2012) Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 32(1):177–182. doi:10.1007/s00296-010-1597-9 CrossRefPubMed Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O, Onat AM, Avan R, Cetin GY, Gul A, Ocal L, Aral O (2012) Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 32(1):177–182. doi:10.​1007/​s00296-010-1597-9 CrossRefPubMed
5.
go back to reference Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32(2):94–124CrossRefPubMed Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32(2):94–124CrossRefPubMed
6.
go back to reference Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Orheumatol 28(4):761–765 Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Orheumatol 28(4):761–765
7.
go back to reference Kunyakham W, Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2012) Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Paci J Allergy Immunol 30(2):152–157 Kunyakham W, Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2012) Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Paci J Allergy Immunol 30(2):152–157
8.
go back to reference Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37(8):895–900CrossRefPubMed Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37(8):895–900CrossRefPubMed
9.
go back to reference Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24(4):654–662PubMed Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24(4):654–662PubMed
10.
go back to reference Migliaresi S, Picillo U, Ambrosone L, Di Palma G, Mallozzi M, Tesone ER, Tirri G (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3(1):37–41CrossRefPubMed Migliaresi S, Picillo U, Ambrosone L, Di Palma G, Mallozzi M, Tesone ER, Tirri G (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3(1):37–41CrossRefPubMed
11.
go back to reference Cho SK, Sung YK, Choi CB, Bae SC (2012) Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int 32(12):3851–3856. doi:10.1007/s00296-011-2312-1 CrossRefPubMed Cho SK, Sung YK, Choi CB, Bae SC (2012) Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int 32(12):3851–3856. doi:10.​1007/​s00296-011-2312-1 CrossRefPubMed
12.
16.
go back to reference Yamaguchi R, Yamamoto T, Motomura G, Ikemura S, Iwamoto Y (2011) Incidence of nontraumatic osteonecrosis of the femoral head in the Japanese population. Arthritis Rheum 63(10):3169–3173. doi:10.1002/art.30484 CrossRefPubMed Yamaguchi R, Yamamoto T, Motomura G, Ikemura S, Iwamoto Y (2011) Incidence of nontraumatic osteonecrosis of the femoral head in the Japanese population. Arthritis Rheum 63(10):3169–3173. doi:10.​1002/​art.​30484 CrossRefPubMed
17.
go back to reference Nakamura J, Saisu T, Yamashita K, Suzuki C, Kamegaya M, Takahashi K (2010) Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum 62(2):609–615. doi:10.1002/art.27236 PubMed Nakamura J, Saisu T, Yamashita K, Suzuki C, Kamegaya M, Takahashi K (2010) Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum 62(2):609–615. doi:10.​1002/​art.​27236 PubMed
18.
go back to reference Asherson RA, Liote F, Page B, Meyer O, Buchanan N, Khamashta MA, Jungers P, Hughes GR (1993) Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 20(2):284–288PubMed Asherson RA, Liote F, Page B, Meyer O, Buchanan N, Khamashta MA, Jungers P, Hughes GR (1993) Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 20(2):284–288PubMed
19.
go back to reference Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, Moriya H (2001) Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 60(12):1145–1148CrossRefPubMedCentralPubMed Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, Moriya H (2001) Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 60(12):1145–1148CrossRefPubMedCentralPubMed
20.
go back to reference Sung YK, Hur NW, Sinskey JL, Park D, Bae SC (2007) Assessment of damage in Korean patients with systemic lupus erythematosus. J Rheumatol 34(5):987–991PubMed Sung YK, Hur NW, Sinskey JL, Park D, Bae SC (2007) Assessment of damage in Korean patients with systemic lupus erythematosus. J Rheumatol 34(5):987–991PubMed
21.
22.
go back to reference Nagasawa K, Ishii Y, Mayumi T, Tada Y, Ueda A, Yamauchi Y, Kusaba T, Niho Y (1989) Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48(8):672–676CrossRefPubMedCentralPubMed Nagasawa K, Ishii Y, Mayumi T, Tada Y, Ueda A, Yamauchi Y, Kusaba T, Niho Y (1989) Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48(8):672–676CrossRefPubMedCentralPubMed
23.
go back to reference Calvo-Alen J, McGwin G, Toloza S, Fernandez M, Roseman JM, Bastian HM, Cepeda EJ, Gonzalez EB, Baethge BA, Fessler BJ, Vila LM, Reveille JD, Alarcon GS (2006) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study. Ann Rheum Dis 65(6):785–790. doi:10.1136/ard.2005.040428 CrossRefPubMedCentralPubMed Calvo-Alen J, McGwin G, Toloza S, Fernandez M, Roseman JM, Bastian HM, Cepeda EJ, Gonzalez EB, Baethge BA, Fessler BJ, Vila LM, Reveille JD, Alarcon GS (2006) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study. Ann Rheum Dis 65(6):785–790. doi:10.​1136/​ard.​2005.​040428 CrossRefPubMedCentralPubMed
24.
go back to reference Nagasawa K, Tada Y, Koarada S, Horiuchi T, Tsukamoto H, Murai K, Ueda A, Yoshizawa S, Ohta A (2005) Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14(5):385–390CrossRefPubMed Nagasawa K, Tada Y, Koarada S, Horiuchi T, Tsukamoto H, Murai K, Ueda A, Yoshizawa S, Ohta A (2005) Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14(5):385–390CrossRefPubMed
25.
go back to reference Aranow C, Zelicof S, Leslie D, Solomon S, Barland P, Norman A, Klein R, Weinstein A (1997) Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol 24(12):2318–2322PubMed Aranow C, Zelicof S, Leslie D, Solomon S, Barland P, Norman A, Klein R, Weinstein A (1997) Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol 24(12):2318–2322PubMed
26.
go back to reference Kim HA, Song YW (1996) Avascular Necrosis in a corticosteroid-treated rheumatic disease population. J Korean Rheum Assoc 3:110–117 Kim HA, Song YW (1996) Avascular Necrosis in a corticosteroid-treated rheumatic disease population. J Korean Rheum Assoc 3:110–117
27.
go back to reference Prasad R, Ibanez D, Gladman D, Urowitz M (2007) The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case–control study of inception patients. Lupus 16(3):157–162PubMed Prasad R, Ibanez D, Gladman D, Urowitz M (2007) The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case–control study of inception patients. Lupus 16(3):157–162PubMed
28.
go back to reference Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, Marti HP, Ganz R, Frey FJ, Kohler HP (2002) Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 74(8):1147–1152. doi:10.1097/01.tp.0000035848.73883.1b CrossRefPubMed Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, Marti HP, Ganz R, Frey FJ, Kohler HP (2002) Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 74(8):1147–1152. doi:10.​1097/​01.​tp.​0000035848.​73883.​1b CrossRefPubMed
29.
Metadata
Title
Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study
Authors
Young Bin Joo
Yoon-Kyoung Sung
Jee-Seon Shim
Jae-Hoon Kim
Eui-Kyung Lee
Hye-Soon Lee
Sang-Cheol Bae
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3147-3

Other articles of this Issue 5/2015

Rheumatology International 5/2015 Go to the issue

Letter to the Editor - Critique and Appraisal

The lack of efficacy of oxytocin and NSAIDs

Original Article - Cases with a Message

Osseous sarcoidosis: a case series